Blogs
Healthcare and Medtech Research Reports
Mar 13, 2018
Anthera’s Sollpura flops after phase 3 Anthera cut free it’s flopped late-arrange Lilly castoff Sollpura (liprotamase), and now looks for those feared "key choices". Sollpura was out-licensed by Lilly in 2014, and the written work had all the attributes of its failure, back in December 2016 when it posted the info...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper